Department of Health Policy & Management, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.
Regenstrief Institute Inc., Center for Biomedical Informatics, Indianapolis, IN, USA.
West J Nurs Res. 2022 Nov;44(11):1068-1081. doi: 10.1177/01939459211029296. Epub 2021 Jul 8.
Nurse scientists are increasingly interested in conducting secondary research using real world collections of biospecimens and health data. The purposes of this scoping review are to (a) identify federal regulations and norms that bear authority or give guidance over reuse of residual clinical biospecimens and health data, (b) summarize domain experts' interpretations of permissions of such reuse, and (c) summarize key issues for interpreting regulations and norms. Final analysis included 25 manuscripts and 23 regulations and norms. This review illustrates contextual complexity for reusing residual clinical biospecimens and health data, and explores issues such as privacy, confidentiality, and deriving genetic information from biospecimens. Inconsistencies make it difficult to interpret, which regulations or norms apply, or if applicable regulations or norms are congruent. Tools are necessary to support consistent, expert-informed consent processes and downstream reuse of residual clinical biospecimens and health data by nurse scientists.
护士科学家越来越有兴趣使用生物样本和健康数据的真实世界数据集进行二次研究。本范围综述的目的是:(a)确定对重新使用剩余临床生物样本和健康数据具有权威或提供指导的联邦法规和规范;(b)总结领域专家对这种重新使用的许可的解释;(c)总结解释法规和规范的关键问题。最终分析包括 25 篇手稿和 23 项法规和规范。本综述说明了重新使用剩余临床生物样本和健康数据的背景复杂性,并探讨了隐私、保密和从生物样本中获取遗传信息等问题。不一致使得难以解释哪些法规或规范适用,或者适用的法规或规范是否一致。有必要开发工具来支持一致的、专家知情的同意过程,并支持护士科学家对剩余临床生物样本和健康数据的下游重复使用。